Sinopep-Allsino Biopharmaceutical Co. Ltd. A

ST Nuotai released its 2026 half-year report, with first-half net profit attributable to the parent at 215 million yuan, down 30.6% year on year. Operating revenue was 1.14 billion yuan, up 8.7% year on year. Net profit attributable to the parent after deducting non-recurring items was 249 million yuan, down 18.6% year on year. Net operating cash flow was 310 million yuan, down 1.9% year on year. Second-quarter operating revenue was 587 million yuan, up 21.5% year on year, while net profit attributable to the parent was 85.59 million yuan, down 45.6% year on year. The company focuses on peptide drugs and small-molecule chemical drugs, with a strategic layout in oligonucleotide business. It has made progress in product pipelines for diabetes, cardiovascular diseases, and oncology, and has broken through bottlenecks in large-scale production technology for long-chain peptide drugs.